3 ms·
The title is "Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern". Note that althoug
by kens 2y ago
The title is "Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern". Note that although the antibodies were only helpful before infection, "its therapeutic efficacy after infection was limited." Thus, it isn't a treatment. Also, this study was in mice, not humans, so this is something potentially for the future, not something you can use now.
- divbzero 2y agodang, would you be able to update the title for this thread? The full title is too long for HN but could be shortened to: “Bispecific antibodies potently neutralize SARS-CoV-2 variants of concern”.